GU Cancers 2024 | Phase I trial results of HERV-E TCR T Cells in metastatic ccRCC

Rosa Nadal, MD, National Institutes of Health, Bethesda, MD, discusses findings from a Phase I first-in-human trial (NCT03354390) of human endogenous retrovirus type E (HERV-E) TCR transduced T cells in HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC). HERV-E is exclusively expressed in renal cell carcinoma, making it an ideal target for cell therapies. The primary endpoint of safety was met, where no dose-limiting or off-target adverse events were reported. However, despite patients not significantly benefiting from receiving the cell therapy, alternative manufacturing approaches are being developed to enhance their efficacy. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.